Results 51 to 60 of about 352 (104)

Successful Management of Immune Thrombocytopenia Presenting with Lethal Alveolar Hemorrhage

Case Reports in Hematology, 2019
Immune thrombocytopenic purpura (ITP) typically presents with bleeding due to immunologic thrombocytopenia. Severe hemorrhage due to ITP is sometimes lethal, and the urgent recovery of platelets is necessary.
Keiki Nagaharu, Masahiro Masuya, Keiki Kawakami, Naoyuki Katayama   +3 more
doaj   +1 more source

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

Journal of Market Access & Health Policy
Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP).
Nichola Cooper, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James, Mondher Toumi, Anna Tytuła, Carly Rich, Daniel Eriksson   +8 more
doaj   +1 more source

Platelet Satellitism Causing Apparent Loss of Response to Eltrombopag in a Patient With Immune Thrombocytopenia

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 495-497, June 2026.
Torsten Ebeling, Stefanie Huber, Leah Bernadette Klingel, Carlo Zaninetti   +3 more
wiley   +1 more source

Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan

Annals of Hematology
This all-case post-marketing surveillance study in Japan evaluated the safety and effectiveness of romiplostim, a thrombopoietin receptor agonist, in patients with aplastic anemia (AA), a rare disease characterized by pancytopenia.
Mitsuhiro Itagaki, Hiroshi Kuwazawa, Shun Sasaki, Moe Matsuura, Yudai Tanaka, Naoshi Obara   +5 more
doaj   +1 more source

Real-world experience with romiplostim in the management of primary immune thrombocytopenia in Iraqi adult patients

Iraqi Journal of Hematology
BACKGROUND: Low platelet counts resulting from increased platelet breakdown and poor platelet generation are the hallmarks of immune thrombocytopenia (ITP), an autoimmune illness.
Alaadin Sahham Naji, Alhan A. Alkhalidi, Luma Essa Hammodi, Ahmed Mjali   +3 more
doaj   +1 more source

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Journal of Blood Medicine, 2016
Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, 2Division of Hematology, University of Washington, Seattle, WA, USA Abstract: Inhibition of platelet production and mediated by ...
Vishnu P, Aboulafia DM
doaj  

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia

Case Reports in Hematology, 2012
Immune thrombocytopenia is characterized by antibody-mediated platelet destruction and insufficient platelet production resulting in isolated thrombocytopenia in the absence of underlying cause.
Maria Fernanda Gonzalez, Jonathan King Freeman   +1 more
doaj   +1 more source

Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review

Annals of Hematology
Severe aplastic anemia (SAA) is a rare bone marrow failure disorder with high morbidity and mortality, particularly in patients ineligible for hematopoietic stem cell transplantation.
Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Kotb, Haroon Alfadil, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari   +6 more
doaj   +1 more source

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis

Platelets, 2019
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder presenting with low platelet count
Joyce Tumaini Massaro, Yanhui Chen, Zhongling Ke   +2 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source